AR-13324 Ophthalmic Solution 0.01%
DrugAdministered to study eye, once daily (QD) in the morning (AM) for 7 days
NCT Number: NCT01528787
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout the study.
Looking for future studies?
Notify Me18 year–99 year
All sexes
Interventional
Phase 2
Aesthetic Eye Care Institute, Newport Beach, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ophthalmic: Either eye
General/Systemic:
Administered to study eye, once daily (QD) in the morning (AM) for 7 days
Administered to study eye, QD AM for 7 days
Other names: Netarsudil
Administered to study eye, QD AM for 7 days
Administered to study eye, QD AM for 7 days
Time frame: Study treatment was administered for 7 days; starting on Day 2 and ending on Day 8.
The primary efficacy outcome was the mean IOP across subjects within treatment group at each post-treatment timepoint of Day 8.
Instillation of study treatment commenced on Day 2 following measurement of IOP. IOP was measured at 0800, 1000, 1200 and 1600 hours on days 2 and 8. IOP was also measured at 0800 hours on Day 4.
Aerie Pharmaceuticals
Industry
A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of Three Doses of AR-13324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07082816
Eye Diseases, Glaucoma
Dothan, Alabama, United States
View Trial DetailsNCT06441643
Eye Diseases, Glaucoma
Garden Grove, California, United States
View Trial DetailsNCT04630808
Eye Diseases, Glaucoma
Dothan, Alabama, United States
View Trial DetailsNCT03750201
Eye Diseases, Glaucoma
Beersheba, Israel
View Trial Details